| Names | |
|---|---|
| Preferred IUPAC name | choriogonadotropin |
| Other names | Chorionic Gonadotrophin Human Chorionic Gonadotrophin hCG Choriogonadotropin Chorulon |
| Pronunciation | /ˌkɔːr.iˈɒn.ɪk ɡəˌnæd.əˈtrəʊ.fɪn/ |
| Identifiers | |
| CAS Number | 9002-61-3 |
| Beilstein Reference | 14401 |
| ChEBI | CHEBI:37750 |
| ChEMBL | CHEMBL1201519 |
| ChemSpider | 50709 |
| DrugBank | DB00011 |
| ECHA InfoCard | 100044-14-9 |
| EC Number | EC 1.3.99.1 |
| Gmelin Reference | 25219 |
| KEGG | hsa04914 |
| MeSH | D002701 |
| PubChem CID | 16132282 |
| RTECS number | GUJ4XZ01HM |
| UNII | YK1K7E8S7N |
| UN number | UN2814 |
| CompTox Dashboard (EPA) | DTXSID4047032 |
| Properties | |
| Chemical formula | C1007H1690N294O300S7 |
| Molar mass | 36712.96 g/mol |
| Appearance | White, sterile, lyophilized powder |
| Odor | Odorless |
| Density | 1.24 to 1.30 g/cm³ |
| Solubility in water | Soluble in water |
| log P | -3.51 |
| Viscosity | Viscous liquid |
| Dipole moment | 547 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 15.7 J·mol⁻¹·K⁻¹ |
| Pharmacology | |
| ATC code | G03GA01 |
| Hazards | |
| Main hazards | Suspected of damaging fertility or the unborn child. |
| GHS labelling | GHS07, GHS08 |
| Pictograms | G-S02 G-S04 G-S05 G-S07 |
| Signal word | Warning |
| Hazard statements | Hazard statements: May cause allergy or asthma symptoms or breathing difficulties if inhaled. May cause an allergic skin reaction. |
| Precautionary statements | Keep out of the sight and reach of children. Chorionic Gonadotrophin should not be used after the expiry date stated on the packaging. Store in a refrigerator (2°C – 8°C). Do not freeze. Protect from light. |
| NFPA 704 (fire diamond) | Health: 1, Flammability: 0, Instability: 0, Special: -- |
| LD50 (median dose) | LD50 (median dose): Mouse: > 2,000 IU/kg, intravenous |
| NIOSH | NA |
| PEL (Permissible) | Not established |
| REL (Recommended) | 500-1000 IU |
| Related compounds | |
| Related compounds | Gonadotropin Human chorionic gonadotropin (hCG) Luteinizing hormone (LH) Follicle-stimulating hormone (FSH) Menotropins Urofollitropin |
| Identification Aspect | Technical Details from Manufacturer Perspective |
|---|---|
| Product Name & IUPAC Name |
Product Name: Chorionic Gonadotrophin IUPAC Name: The IUPAC name for the main active component is variable, reflecting batch-dependent peptide composition typical of biological extraction processes. Most lots correspond to “chorionic gonadotropin (human),” representing a glycoprotein hormone mixture. |
| Chemical Formula | As an extracted and purified peptide hormone, the formula is complex and not represented by a simple molecular formula. Each preparation may differ in minor side-chain glycosylation. Primary active moiety: C1100H1770N318O336S26 (approximate, for the principal subunit, varies by isoform). |
| Synonyms & Trade Names | Human Chorionic Gonadotropin; hCG; Choriogonadotropin alfa (for recombinant); u-hCG (for urinary-extracted); trade names depend on regional registrations and formulation, such as Pregnyl, Ovidrel, Novarel, and others in commercial pharmaceutical products. |
| HS Code & Customs Classification |
HS Code: 2937.19 Customs Classification: This code is commonly assigned to Hormones, natural or reproduced by synthesis; derivatives and structural analogues, including chain modified polypeptides, for pharmaceutical use. Final classification subject to regional regulatory authorities and product declaration based on the exact product form (bulk API, formulated preparation, diagnostic use, etc.). |
Large-scale manufacturing of chorionic gonadotrophin involves source selection between natural extraction (human urine collection) and recombinant synthesis in cell cultures. The grade defines the route:
Chorionic gonadotrophin’s product grade is dictated by intended use:
End-product performance depends on both upstream manufacturing and final formulation. Lyophilized cake characteristics, solvent compatibility, and aggregation tendencies critically change with minor upstream parameter variation. This drives each lot’s suitability for either finished drug or in-vitro diagnostic kit production. Manufacturers typically provide comprehensive certificate of analysis packages, batch process history, and detailed impurity profiling for partner review before integration into regulated workflows.
Chorionic Gonadotrophin, commonly isolated as a lyophilized powder, exhibits color ranging from off-white to pale yellow. Visual texture differences arise from variations in drying and excipient addition. The finished powder lacks any distinctive odor. Form and particle characteristics are tuned based on intended formulation: clinical injectable, diagnostic reagent, or bulk intermediate.
As a protein-based biological, Chorionic Gonadotrophin denatures rather than melts or boils. Thermal exposure above formulation-specific thresholds causes irreversible degradation, which manifests as solubility loss and aggregate formation. Density and solid-state behavior vary based on excipients and residual solvent profile post-lyophilization, and no industrial measurement targets a single density value due to the product’s amorphous proteinaceous nature.
The active protein structure requires careful pH, temperature, and ionic strength management at every stage. Stability windows differ according to the product grade: pharmaceutical, veterinary, or research. In aqueous environments, degradation accelerates at elevated temperature or non-neutral pH. Contact with oxidizers, or prolonged light exposure, leads to rapid functional loss. Formulation often includes stabilizers to address these sensitivities. Reactivity with incompatible packaging (such as leachable glass or rubber) is controlled by validated compatibility studies.
Reconstitution yields clear to slightly opalescent solutions when prepared with specified isotonic or buffered solvents. High purity grades dissolve at prescribed concentrations with minimal undissolved matter. End-use testing determines the required solvent system and dilution factor. Solubility loss signals denaturation or contamination.
Every batch targets grade-specific activity as defined in international units (IU). Pharmaceutical and veterinary grades are defined by global pharmacopoeia or regional regulatory standards. Research-grade allowances for biological activity range wider, reflecting divergent application needs. Purity and residual host cell protein/DNA tolerances follow final application risk assessment. Final release specification tables are issued with batch C of A and always adjusted to regulator and customer requirements.
Process impurities stem from host cell proteins, DNA, process chemicals, and excipients. Their control depends on the synthesis route and downstream purification adequacy. Limits for each impurity type are established through risk assessment and validated analytical methods. No universal single set of numbers covers all grades. Limits are imposed to maintain safety for injectable use and batch-to-batch reproducibility for diagnostics.
Activity is quantified by bioassays or immunoassays standardized to international reference preparations. Purity, identity, and impurity quantification are controlled by HPLC, SDS-PAGE, ELISA, and nucleic acid-based methods. Analytical method selection aligns with the grade and regulatory expectation, and ongoing proficiency validation supports reliability of test results.
The choice of biological source—typically human placental extract or recombinant cell culture—directly shapes the impurity profile, manufacturing cost, and regulatory scrutiny. Source selection always undergoes documented traceability and biological protection protocol review. Recombinant routes increasingly replace extraction-based methods for regulatory acceptance, ethical, and supply continuity reasons.
Placental extraction methods demand batch-controlled solvent extraction, precipitation, and bioactivity-guided pooling. Recombinant production requires cell line engineering, controlled fermentation, induction, and secretion harvesting. Mechanisms affecting yield and post-translational integrity depend on route and host system. Process selection leans toward reproducibility, impurity minimization, and scalability.
Critical controls center on temperature, pH, and residence time during extraction, chromatography, and diafiltration stages. Purification employs multi-stage chromatography—affinity, ion-exchange, and size-exclusion—tailored to maximize bioactivity recovery and minimize non-specific protein carryover. Filtration removes particulates and ensures sterility for injectable use. In-process sampling monitors host protein/DNA reduction, process leachables, and aggregate formation.
Batch consistency relies on validated upstream and downstream steps, always bracketed by in-process controls and final release testing. Key batch release criteria include specified bioactivity, host impurity limits, pyrogen/endotoxin control, and microbial safety verification. Release only occurs after cross-referencing all documentation, test results, and regulatory guidance compliance.
Chorionic Gonadotrophin reacts easily to small molecule conjugation and enzymatic cleavage. Derivatization or PEGylation extends serum half-life for clinical or diagnostic uses. Downstream post-processing, such as labeling with biotin or fluorescent tags, follows after activity-preserving solvent and catalyst selection. Deamidation, oxidation, and aggregation represent unwanted spontaneous reactions during incorrect storage or formulation errors.
Reactions tending to modify the protein—conjugation, labeling, or site-directed mutagenesis—occur in mild aqueous buffered systems, low temperatures, and absence of denaturing agents. Catalyst or cofactor inclusion depends on the chemical target and solvent compatibility with protein structure.
Manufacturers develop derivatives for extended-release pharmaceuticals, improved diagnostic sensitivity, or custom research reagents. Some modifications require additional purification rounds to separate active forms from degraded or mis-reacted species.
Unformulated solid product requires dry, low-temperature storage—commonly refrigerated or frozen environments, with protection from humidity and light. Storage atmospheres depend on sensitivity to oxygen and risk of hydrolytic or oxidative degradation. Pharmaceutical products are stored under Good Manufacturing Practice (GMP) conditions; diagnostic and research grades follow internal protocol or customer request.
Containers are validated for interaction and leachable risk. Glass vials are usual, sometimes with polymeric stoppers or aluminum seals. Studies verify the absence of extractable components and retention of protein stability over shelf life under intended storage and shipment conditions.
Label shelf life relies on real-time and accelerated stability data sets. The timeline varies with formulation, grade, and packaging. Degradation manifests visually as discoloration, precipitation, or loss of solubility. Loss of biological activity measured through routine QC triggers withdrawal of the batch from supply.
Classification reflects the low acute hazard for handling lyophilized bulk in manufacturing, but injectable pharmaceutical use triggers critical pharmacovigilance and risk management. Laboratory and production teams are trained on safe handling to minimize accidental exposure and environmental contamination. Detailed safety sheets underscore the risks of direct exposure, improper disposal, or use outside licensed limits.
Safety data for each grade draws on pre-clinical and clinical submissions, with toxicology specific to route of exposure and intended use. For production and lab staff, inhalation, dermal, and oral exposures are controlled by ventilation, gloves, and containment procedures in keeping with internal risk assessment.
Manufacturers operate within well-established occupational exposure bands for biologics. Site-specific safety protocols include closed-system charging, personal protective equipment, and automated batch documentation. Incident response plans address accidental spillage, personnel exposure, and product loss by validated inactivation and cleanup procedures.
Production capacity for Chorionic Gonadotrophin depends on extraction yield, upstream biological material access, purification throughput, and batch release success rate. Availability fluctuates with the efficiency of biosource collection, presence of seasonal variation, and plant scheduling. For pharmaceutical-grade material, batch release hinges on passing potency and impurity profile limits. Capacity allocation between domestic and export contracts is planned annually with buffer for regulatory batch re-testing or rejected lots. Capacity expansion often involves capital investment in lyophilization lines and primary containment for biopharmaceuticals. Current technical bottlenecks include bottling line throughput and compliance-driven holds during lot release for specific markets.
Lead time for Chorionic Gonadotrophin typically ranges from 6 to 16 weeks, considering cell culture or biological material extraction, purification, stabilizer addition, and finished product testing. Minimum order quantities align with batch yield; MOQ for pharmaceutical grades is set in consultation with process scale and downstream packaging split needs. Sterile API and clinical use grades will require longer release cycles due to additional sterility, viral clearance, and potency re-testing.
Packaging varies by grade, customer application, and regulatory requirement. Lyophilized powder is most often packed in Type I amber glass vials with inert closures for API, supported with multipack shipper boxes suitable for refrigerated logistics. Bulk supply for downstream formulation ships in larger, validated containers with sub-batch seal assurance. Customer-defined reconstitution buffer and secondary packaging can be provided when specifically requested and validated for compliance.
Shipments are executed with validated cold chain logistics for cold-stable grades, including temperature monitoring and deviation reporting. Customs, import permit, and documentation vary by consignee country; pre-shipment certificate requirements may extend release times. Payment terms generally follow irrevocable L/C at sight or T/T on pro-forma invoice, defined by customer status, location, and contract length. Regulatory destination determines whether additional analytical documentation or re-release batch testing is required before dispatch.
The extraction of Chorionic Gonadotrophin relies on high-quality biological material, subject to yield fluctuation, seasonal collection constraints, and veterinary compliance for animal-derived sources. Key cost drivers include the cost of serum/raw extract, critical process reagents, chromatography resin longevity, and batch throughput losses from failed releases. In high-purity grades, additional purification steps and extended analytical testing increase production cost. Fluctuations stem from biological source availability, rising costs of GMP reagents, and shifts in compliance costs due to regulatory changes or supply chain interruptions. Import restrictions, veterinary health declarations, or epidemic outbreaks have historically contributed to raw material cost hikes and downstream shortage pricing events.
Price differences among grades arise mainly from potency, contamination thresholds, batch traceability, and analytical release profile. Material certified for GMP-compliant pharmaceutical use commands a premium due to detailed documentation, extended stability studies, individual lot testing, and full chain-of-custody tracing. Packaging further impacts price due to vial format, cold chain validation, and secondary labeling requirements for regulated endpoints. Higher purity and more stringent endotoxin, host cell protein, or viral load specifications mean longer process times and more expensive QA, reflected in customer end pricing. Documentation for export-specific certifications also introduces incremental pricing over domestic grades.
Demand for Chorionic Gonadotrophin tracks with human and veterinary pharmaceutical consumption. Largest demand centers include North America, EU, Japan, India, and China, with each region maintaining distinct regulatory and documentation needs. Shortages periodically arise from upstream biological source interruptions, regulatory embargoes, or process contamination events prompting manufacturer recalls.
Across key markets, price trends in 2026 will depend on changes in biological source supply, regulatory tightening for veterinary diseases, cost escalation in high-purity process inputs, and evolving global supply chain disruptions. China and India may experience tightening of exportable high-purity volumes as domestic pharmaceutical consumption grows. Regulatory upgrades in the EU and US could further increase compliance costs, lifting unit prices for certified grades. Market consolidation and fewer certified large-scale manufacturers may reduce price competition at upper regulatory and purity segments.
Analysis based on internal release batch cost audits, regional export volume data, customer RFQ histories, and public regulatory filings. Supplier-side intelligence draws from participation in international exhibitions, raw material sourcing forums, and customer-reported market disruptions. Cross-reference with regulatory agency alerts and international trade data sets forms the external validation method.
Veterinary outbreaks in primary material sourcing regions have triggered additional lot holding and animal traceability requirements, impacting seasonal supply consistency. Several regions have heightened import permit scrutiny, occasionally leading to consignment delays pending certificate clarifications.
Updated monograph requirements in major pharmacopeias now require additional impurity and residual solvent documentation, increasing pre-release testing times. GMP audit guidelines have shifted focus toward viral risk assessment and supplier vetting, necessitating closer collaboration with raw material source partners. Documentation harmonization requirements and new serialization guidelines shape re-packaging and labeling instructions for export-grade products.
Manufacturers have invested in upstream quality partnerships for animal source validation and third-party GMP certification renewals. Contingency stock planning and qualification of secondary validated suppliers for critical reagents have reduced production stoppage risks. Cross-training in analytical labs and expanded post-release QA sampling have improved batch acceptance rates. Ongoing dialogue with regulators ensures timely compliance updates and reduced export delay risks.
| Application | Recommended Grade | Critical Properties |
|---|---|---|
| Human Pharmaceuticals | Pharma/Injectable Grade | Biological activity units, sterility, pyrogen status, absence of detectable endotoxin, compliance with regional pharmacopoeia |
| Veterinary Medical Use | Veterinary Grade | Activity range, residual solvent load, extractables, host cell protein content |
| Research & Diagnostics | Research/Laboratory Grade | Activity units, extractables, batch traceability, form (liquid/lyophilized) |
Start by confirming the intended field – human therapeutic, veterinary, or laboratory/research. Internal batch specifications and release criteria are mapped to the downstream application field. Selection at this stage sets the overall framework for QC, documentation, and regulatory compliance handling.
Human application typically follows official pharmacopeia (USP, EP, JP) or local market authority rules. Veterinary and laboratory use often have more varied acceptance criteria, but process traceability and control documentation remain necessary. Engage internal regulatory affairs during early discussions to clarify target jurisdiction needs.
Purity and biological activity requirements differ by application. Pharma grade demands robust purification with strict in-process monitoring for host cell protein, DNA, residual solvents, and bioburden. Veterinary and lab grades allow broader profiles but require process controls to ensure batch-to-batch consistency.
Process configuration and lot size allocation often depend on volume and end-user price targets. Human pharmaceutical grade production typically requires low-volume, high-control processes, driving cost per unit higher. Veterinary or laboratory runs may consolidate output to control costs, provided batch integrity and traceability are maintained.
Product evaluation under real-world conditions is critical. As a manufacturer, we support pilot sample requests aligned with specified application needs. Customers can validate not only performance parameters but also handling, solubility, and compatibility within their formulation or assay system. Batch-level documentation supports qualification and technical due diligence.
Production of chorionic gonadotrophin involves multi-stage biological extraction and purification steps, each governed by internal quality protocols. Facility operations maintain certification under ISO 9001 for quality management. Beyond this, cGMP compliance governs process consistency, traceability, and documentation from raw material intake through to packaging and batch release. For pharmaceutical-grade material, regulatory audit readiness is maintained through systematic internal audits, records of environmental monitoring, and routine process validation.
Chorionic gonadotrophin specifications can shift between pharmaceutical, clinical diagnostic, and research grades; each grade faces a distinct certification and testing regime. For regulated pharmaceutical supply, product documentation relies on pharmacopeial reference (e.g., USP, EP) and product is only released per grade-specific QC lot number and final review by a qualified person. Where required, DMF support and regulatory documentation accompany commercial shipments. Country or customer registration dossiers may require supplementary in-house reports, certificate of analysis, sterility assurance documentation, and species-specific validation data.
Comprehensive documentation includes full traceability of animal source, process batch log, in-process control data, and release analysis. Test reports detail hormonal activity, protein quantification, immunological profile, and contaminant screening according to grade requirements. End-users requiring documentation for regulatory submission can request raw data set, stability reports (real-time and accelerated), endotoxin result history, and transportation validation, all issued based on actual batch records.
Ongoing B2B deliveries to clinical and industrial partners rely on stable batch scheduling, raw material forward contracting, and a dedicated process line. Capacity allocation aligns with cyclical demand forecast and risk-managed inventory policy, particularly where customer downstream production cycles are sensitive to supply timing. Strategic partnerships benefit from annual contract production and volume-tiered pricing, with prioritized batch reservation for long-term cooperation plans.
Critical raw material qualification and supplier vetting reduce batch-to-batch variation risks. Process equipment redundancy and dual-site production infrastructure further reduce any risk of interruption. For high-volume programs, supply forecasts guide both upstream sourcing and downstream fill/finish capacity planning, ensuring availability over contract duration.
Sample applications commence through a direct technical pre-qualification, identifying the required grade, end-use context, and necessary documentation. Small-scale samples are drawn from recently certified batches, with documentation matching the requested certification regime. Turnaround times for sample provision match internal test completion for each grade (e.g., sterility, identity, potency), so timelines depend principally on grade and analytical regime.
Flexible supply contracts allow for call-off orders, schedule changes, and volume adjustments in accordance with production lead times and mutual buffer stock arrangements. Terms expressly define batch acceptance criteria, co-validation requirements, and mechanisms for joint deviation investigation in the event of out-of-specification findings. For tailored projects—such as new route development or non-standard vialing—joint project management ensures milestones, release standards, and documentation sequences are agreed upon before scale-up.
Within the scope of industrial-scale Chorionic Gonadotrophin production, research increasingly focuses on optimizing yield per batch and minimizing product-variant impurities. Most facilities prioritize process efficiency for extraction, purification, and formulation, reflecting customer expectations on product consistency and trace impurities. There is clear movement toward satisfying pharmaceutical regulatory environments, which means constant revision of in-process analytics and downstream product release protocols to reflect current pharmacopeial demands.
Process integration between raw material sourcing and purification strategies stands out as a main driver for batch-to-batch consistency. Sourcing of raw chorion tissue is often subject to regional regulatory oversight, which has pushed manufacturers to invest in traceable supply chains and non-animal recombinant routes, notably investigated for their potential to limit biological impurity loads.
Beyond classical reproductive medicine, emerging demand for Chorionic Gonadotrophin includes assisted reproductive technology, expansion into veterinary formulations, and specific research-grade reagents. Each segment exhibits its own sensitivity to impurity spectrum, protein conformation, and stabilizer systems, with custom-grade definition increasing in response to requests from specialty clinical users. Veterinary market expansion, for instance, often requires differentiated formulation and concentration ranges, dictated by animal species and regulatory territory.
Key technical barriers during large-scale production revolve around controlling host-specific impurities, protease degradation, and glycoform heterogeneity. Moving from animal-derived materials to recombinant expression systems has yielded breakthroughs in purity profiles and scalability, though each expression system introduces its own technical risk points and handling challenges.
Ongoing optimization of in-line chromatographic purification and real-time release testing continues to dictate the feasibility of short production lead times. Addressing aggregation or denaturation during lyophilization and storage persists as a mainstays in formulation R&D.
Demand for GMP-grade Chorionic Gonadotrophin is projected to remain solid in fertility clinics and controlled pharmaceutical formulations. Market growth in emerging regions aligns with infrastructure improvements, tightening regulatory frameworks, and shifting clinical guidelines on assisted reproduction. Substitute biotechnological routes are gradually achieving regulatory acceptance, promising greater availability of customized grades.
Ongoing investment in recombinant technology is likely to increase the proportion of animal-free and chemically defined product supply, but full conversion depends on regulatory dynamics and customer trust in biosimilar performance data. Manufacturing control points continue to migrate from off-line batch analytics to continuously monitored, closed-loop automated systems, which allows for earlier detection of batch deviations and run-to-run learning.
Efforts at our facility prioritize solvent recovery, reduced reliance on animal-derived inputs, and minimization of complex single-use plastics in the process chain. Full traceability for each batch, with enhanced in-process washing and disposal stream purification, supports compliance with green chemistry and environmental safety mandates set by both regional and multinational regulatory bodies.
Direct access to on-site technical and QC staff assures immediate guidance on handling, reconstitution, and application-specific formulation. Consultation sessions extend to testing protocols adapted to customer-specific downstream use—clinical, veterinary, or research—allowing for tailored recommendations on optimal diluents and excipient compatibility.
Our technical team regularly supports dosage form developers and downstream processors with process transfer planning, viscosity management, and aggregation prevention. For veterinary and specialty research applications, specialists advise optimal storage and reconstitution strategies that correlate with required biological activity and minimize product loss.
We commit to investigating customer-reported deviations or performance anomalies through full batch trace-back and, where necessary, representative lot re-sampling. Long-term partnerships often include periodic technical training at the user’s facility and updates reflecting regulatory and analytical changes affecting product application or compliance documentation requirements.
As a direct manufacturer of Chorionic Gonadotrophin, control of the production environment defines how we approach consistency and dependability. All processing, purification, and finishing steps run on site. Lab and pilot teams work together at every batch stage. No aspect is left to chance or outsourced, which gives our clients a predictable standard and timelines that fit into planning cycles for commercial production.
Manufacturers in animal health and pharmaceutical supply turn to Chorionic Gonadotrophin for established performance in ovulation induction protocols, infertility treatment, and reproductive management. Veterinary groups use this compound to optimize artificial insemination efficiency for herd health and animal breeding. Specialty biotech segments apply it for hormone assay calibration and fertility research, taking advantage of its proven bioactivity.
Our plant operates under rigorous quality management. Every release lot undergoes full spectrum analytics to document purity, activity, and absence of cross contaminants. We maintain detailed records for each batch—including raw material sourcing and process chain audit—making trend tracking and compliance straightforward. No product reaches packaging unless it passes both instrument testing and in-process review points. Process engineers implement corrective measures immediately if any deviation occurs, avoiding downstream surprises for customers.
Finished product leaves our facility in packaging specified by the end user, whether sealed glass containers, vacuum-packed vials, or bulk containers for commercial processors. Stability assessments guide decisions on packaging material and fill sizes. Long-term contracts benefit from flexible scheduling and supply forecasts, so shutdown planning and inventory optimization stay under control. Regular supply assessments allow us to handle seasonal demand surges and custom run requests with advance planning, not emergency response.
Our application specialists support process engineering teams at the facility level, reviewing protocols and documenting manufacturing workflow impact. We supply certificates of analysis for each lot, respond to technical queries from formulation scientists, and provide documentation aligned with regulatory submissions if needed. Adjustment of concentration or format is handled directly between buyer tech teams and our manufacturing chemists. Close feedback between customer R&D groups and our production engineers lets us adapt to evolving process or specification demands without delay.
Commercial manufacturers, distributors, and procurement professionals integrate our Chorionic Gonadotrophin supply into their sourcing and planning for a single main reason: predictable, direct-from-plant reliability. Removal of third-party risk means no surprises in labelling, shipment scheduling, or spec adjustments. Onsite testing and documentation control limit non-conformances and support audits by end-users or regulatory agencies. The ability to contract directly with a producing plant cuts negotiation friction, keeps specifications transparent, and gives sourcing teams leverage in cost projections and continuity planning.
| Aspect | Direct Manufacturer Value |
|---|---|
| Production control | Onsite, with no external subcontracting |
| Analytical support | Instrument-based batch release and full records |
| Packing options | Client-specified, stability-tested materials |
| Technical access | Direct dialogue with factory chemists and engineers |
| Supply assurance | Production reservations for regular buyers |
Direct control of the full Chorionic Gonadotrophin production process lets us deliver reliability and business certainty to industrial buyers—built on technical diligence, not promises.
As a direct manufacturer, we find ourselves addressing a routine but important set of questions about human Chorionic Gonadotrophin—mainly, regarding the molecular weight and whether the source is urinary or recombinant. These details hold weight for any partner in pharmaceutical formulation, research, or quality assurance, as performance and regulatory acceptance hinge on transparency and technical integrity. So, clarity about the origins and characteristics of the hormone becomes a matter of uninterrupted product supply and reliable clinical outcomes.
Molecular weight for human Chorionic Gonadotrophin consistently falls in the range of 36,000 to 38,000 Daltons. This value comes from the combination of its alpha and beta subunits, which together form a glycoprotein structure. Every batch our team produces is validated by analytical techniques, such as SDS-PAGE and mass spectrometry, ensuring that customers work with a consistent biomolecule profile. Consistency in molecular mass confirms the correct structure, which directly impacts stability and biological activity.
Chorionic Gonadotrophin production historically relies on urine collected from pregnant women, refined through advanced purification. We continue to operate at-scale processing for urinary-derived hormone to meet the longstanding needs of certain regulatory or pharmacopeial requirements. The drive behind this source remains simple—some therapeutic and diagnostic applications call for the native glycosylation pattern present only in urinary-extracted hormone, which affects receptor affinity and bioactivity in clinical practice.
With improvements in genetic engineering, recombinant Chorionic Gonadotrophin has become a viable alternative where traceability, allergen reduction, and batch-to-batch uniformity carry added value. Recombinant forms offer the benefit of animal component-free manufacturing, lessening regulatory hurdles in some markets and lowering the chance of contamination. Our facilities are designed to support both technologies in parallel, with strict segregation and dedicated quality assurance for each line.
The choice between urinary and recombinant sources often prompts questions about comparative yields, analytical verification, and downstream processing. From our vantage point, the technology chosen must also account for the intended application. For example, some markets still require urinary-derived product for compliance with regional pharmacopeias or clinical preference. Other markets trend toward recombinant, seeking uninterrupted supply, reduced biological risk, or tailored glycosylation profiles. Our catalog and technical support cover both, so we match exact formulation criteria without shortcuts or opaque sourcing.
Every kilogram of hormone that leaves our facility has been fully qualified, whether sourced from large-scale urinary pools or cultivated through cell culture methods. Both production streams follow strict GMP, with extensive in-process testing to catch deviations before final release. Documents tracking source material, production batches, and molecular characterization back up our shipments. These steps cut down on ambiguity, prevent supply chain questions, and reinforce confidence with auditors and regulatory authorities.
Bringing these details out of the shadows ensures that our customers face fewer interruptions, and can justify every batch they formulate or test. By holding both urinary and recombinant technologies under one roof, our manufacturing remains flexible, robust, and responsive. With every lot, we combine technical discipline with full traceability, so each partner has what they need to meet their end-use, regulatory, and quality challenges head-on without compromise.
As a dedicated manufacturer of chorionic gonadotrophin, transparency with our partners is important. Minimum order quantity (MOQ) and lead time for this material always reflect the realities of our factory capacity, current market demand, and the rigor of our quality assurance process. Every batch requires careful planning across biological sourcing, purification, and analytical stages, so timing and scale can vary based on upstream variables as well as final product requirements.
Our standard MOQ stands at 100 grams per batch for bulk requests. Producing below this threshold drives costs up due to the scale of biological material handling and cGMP compliance. Each run involves careful extraction and purification, so operations at a substandard quantity disrupt production efficiency and may jeopardize technical consistency between lots. From years of experience, such a minimum offers realistic balance between procurement needs and sustainable factory throughput. For those requiring smaller trial quantities (under 100 grams), discussion with our technical team helps clarify feasibility based on current batch planning and scheduling.
Typical lead time ranges from 6 to 8 weeks following final contract confirmation and receipt of all necessary documentation. This timeline captures the reality of each production step—from acquisition of certified source material to the end-stage analytical release. Our cold-chain logistics and compliance paperwork move in parallel with the last phase of QC, ensuring that delivery does not stall on regulatory detail. North American and European delivery windows may vary modestly owing to transit time and import review.
The last two years have brought notable shifts in supply for biologically derived APIs. Demand for chorionic gonadotrophin varies due to clinical trial cycles and market registrations, so sudden industry shifts or new product launches can amplify the challenge of maintaining spot availability. Careful scheduling helps us shield customers from most spikes, but unplanned regulatory audits or raw material disruptions may still affect timing. Allocating production slots by confirmed purchase order secures lead time against disruptive market swings. Our contract terms and forecasting expertise minimize risk of allocation delays.
Process upgrades and periodic scale-up projects have strengthened output over the past year. Our QC lab continually adapts analytical controls to match heightened regulatory scrutiny, balancing compliance and delivery commitments. By investing in staff training and automated monitoring, we reduce risk of batch deviation and rework, keeping customers on schedule.
Our technical team remains available for any further details about our capacity, next available manufacturing draft, or documentation required for regulatory submissions. Supply is not a simple transaction for us; it is a long-term partnership built on shared demand forecasts and transparent communication. Clients relying on biological actives know that small details in procurement policy influence every downstream milestone. We welcome questions about lot reservation, stability data, or tailored logistics solutions—all informed directly by our manufacturing workflow. Expectations of trust and precise timing drive our daily operations on the production floor.
Producing Chorionic Gonadotrophin comes with strict compliance expectations, set not just by local authorities, but by agencies across multiple markets. From our factory, every batch leaves only after we ensure its documentation aligns with each region's pharmaceutical and customs regulations. Exporting to the European Union, for example, means current GMP status, complete traceability, and batch-to-batch reproducibility are not just industry standards—they’re legal requirements. The same holds for shipments into North America and Asia, where authorities routinely ask for verifiable manufacturer records and authentication.
With every lot, we supply a complete Certificate of Analysis (COA), detailing assay method, physical properties, purity, and all relevant analytical results for that batch. Our COA format follows up-to-date regulatory language for each receiving country. Agents at customs and health offices want original COAs showing actual batch test results, not just template certificates.
We prepare and update our Material Safety Data Sheet (MSDS) regularly, based on real-world handling feedback and ongoing hazard assessments. Our documentation references the latest standards, including GHS alignment, transportation code requirements, and applicable environmental precautions. When air or sea shipment demands additional declarations or translated documents, the technical team prepares those directly.
Years of shipping to regional customers taught us that missing or outdated paperwork can cause immediate shipment delays, sometimes earning batches a mandatory re-export order or, worse, destruction fees. We noticed the most common problems happen when regulatory authorities request breakdowns of source materials or require detail on impurity profiles. To address this, our dossiers include up-to-date compliance statements, validation summaries, and a formal declaration of origin.
For each country, the legal requirements shift. The Chinese FDA expects expanded dossiers with additional trace contaminant assessment. The European Union asks for detailed GDP (Good Distribution Practice) chains. The U.S. FDA looks for proof of animal tissue origin controls and cold-chain validation protocols. We handle country-specific pharma registration paperwork internally to avoid holdups.
To keep up with stricter international standards, our laboratory gets regular equipment upgrades, and technical training cycles run year-round. Auditors don’t accept manufacturer claims unless backed by original records. It takes precise documentation, not guesswork, to show regulators and customers that our Chorionic Gonadotrophin is fully traceable and compliant. Our quality team continually reviews feedback from past export cases, updating documentation templates and database entries as regional laws evolve.
From order confirmation to final delivery, we deliver full transparency about our Chorionic Gonadotrophin’s origins, test results, and safe handling requirements. Buyers receive genuine, lot-specific paperwork—never templates recycled from old batches. No batch ships without signed, original documentation matching the region’s current standards.
By treating regulatory compliance as a technical, scientific process, we protect customers from shipment delays, customs disputes, and compliance risks. The effort invested in proper certification and safety data pays back in smooth imports, assurance for downstream handlers, and uninterrupted supply chains for all partners.
For product inquiries, sample requests, quotations or after-sales support, please feel free to contact me directly via sales3@ascent-chem.com, +8615365186327 or WhatsApp: +8615365186327
